MX2021012515A - Methods and compositions for treating respiratory arrhythmias. - Google Patents

Methods and compositions for treating respiratory arrhythmias.

Info

Publication number
MX2021012515A
MX2021012515A MX2021012515A MX2021012515A MX2021012515A MX 2021012515 A MX2021012515 A MX 2021012515A MX 2021012515 A MX2021012515 A MX 2021012515A MX 2021012515 A MX2021012515 A MX 2021012515A MX 2021012515 A MX2021012515 A MX 2021012515A
Authority
MX
Mexico
Prior art keywords
compositions
methods
treating respiratory
arrhythmias
respiratory arrhythmias
Prior art date
Application number
MX2021012515A
Other languages
Spanish (es)
Inventor
Adam Kievman
Mallory Kievman
Abraham Friedman
Bartholomew J Bacak
Original Assignee
Meter Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meter Health Inc filed Critical Meter Health Inc
Publication of MX2021012515A publication Critical patent/MX2021012515A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present disclosure relates to compositions to perturb neural circuits and/or the brainstem respiratory network and methods of use thereof.
MX2021012515A 2019-04-18 2020-04-17 Methods and compositions for treating respiratory arrhythmias. MX2021012515A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962835691P 2019-04-18 2019-04-18
PCT/US2020/028708 WO2020214924A1 (en) 2019-04-18 2020-04-17 Methods and compositions for treating respiratory arrhythmias

Publications (1)

Publication Number Publication Date
MX2021012515A true MX2021012515A (en) 2021-12-10

Family

ID=72837979

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012515A MX2021012515A (en) 2019-04-18 2020-04-17 Methods and compositions for treating respiratory arrhythmias.

Country Status (13)

Country Link
US (1) US20220192989A1 (en)
EP (1) EP3955952A4 (en)
JP (1) JP2022529290A (en)
KR (1) KR20220003512A (en)
CN (1) CN113766932A (en)
AU (1) AU2020257415A1 (en)
BR (1) BR112021020690A2 (en)
CA (1) CA3136711A1 (en)
IL (1) IL287219A (en)
MX (1) MX2021012515A (en)
SG (1) SG11202111339WA (en)
WO (1) WO2020214924A1 (en)
ZA (1) ZA202107874B (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2455050C (en) * 2001-08-15 2007-02-20 Pharmacia & Upjohn Company Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene) methyl]-2, 4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof
US20040110803A1 (en) * 2002-09-13 2004-06-10 Hossein Dovlatabadi Methods and compositions for the use of D-malic acid to decrease serum triglyceride, cholesterol and lipoprotein levels
JP5039134B2 (en) * 2006-06-12 2012-10-03 フイルメニツヒ ソシエテ アノニム Stinging and salivary secretion composition
ES2757623T3 (en) * 2012-07-25 2020-04-29 Broad Inst Inc Inducible DNA binding proteins and genomic disruption tools and applications thereof

Also Published As

Publication number Publication date
JP2022529290A (en) 2022-06-20
CA3136711A1 (en) 2020-10-22
CN113766932A (en) 2021-12-07
AU2020257415A1 (en) 2021-11-11
EP3955952A1 (en) 2022-02-23
WO2020214924A1 (en) 2020-10-22
EP3955952A4 (en) 2023-01-25
SG11202111339WA (en) 2021-11-29
BR112021020690A2 (en) 2021-12-14
IL287219A (en) 2021-12-01
US20220192989A1 (en) 2022-06-23
KR20220003512A (en) 2022-01-10
ZA202107874B (en) 2023-07-26

Similar Documents

Publication Publication Date Title
MX2019014514A (en) Compounds for treating huntington's disease.
MX2020001732A (en) Treatment of cns conditions.
ZA201701460B (en) Gamma-diketones for treatment and prevention of aging skin and wrinkles
MX2017016424A (en) Compounds for use in treating neuromuscular disorders.
PH12017500829A1 (en) 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treating alzheimer's disease
MX2021003905A (en) Modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders.
PH12021550324A1 (en) 5 to 7 membered heterocyclic amides as jak inhibitors
MX2020000523A (en) Isochroman compounds and uses thereof.
PH12020550023A1 (en) Compositions for treating stress-related disorders
MX2023012048A (en) Compositions and methods for inhibiting ketohexokinase (khk).
WO2020021477A3 (en) Compositions and methods for treating the eye
MX2021001471A (en) Substituted benzimidazoles as pad4 inhibitors.
MX2022015456A (en) Maca compositions and methods of use.
JOP20190241B1 (en) Epinephrine spray formulations
WO2020021480A3 (en) Compositions and methods for treating the eye
MX2018009662A (en) Method and pharmaceutical composition for treatment of neurodegeneration.
MX2020008991A (en) Methods for altering body composition.
CL2021002878A1 (en) Treatment and prevention of metabolic diseases
MX2021002652A (en) Use of casein kinase 1 inhibitors for treating vascular diseases.
MX2023005591A (en) Methods of treating diseases and disorders.
MX2020011826A (en) Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof.
WO2019040105A3 (en) Compounds, salts thereof and their use in the treatment of diseases
MX2022012404A (en) Compositions comprising 15-hepe for treating or preventing hematologic disorders, and/or related diseases.
MX2019007041A (en) Methods and compositions for treating parkinson's disease.
MX2021012515A (en) Methods and compositions for treating respiratory arrhythmias.